Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Auto Added by WPeMatico
Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment. The post Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results appeared first on Investor’s Business Daily.
Evommune stock dropped Wednesday after its experimental eczema treatment flopped in midstage testing. The bearish news followed another miss for the drug in treating hives. The post This Biotech Has Lost 50%-Plus On Just One Drug; Why It’s Still Trucking…
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders. The post IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target? appeared first…
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone. The post Travere Therapeutics Outlook Brightens As Turnaround Looms appeared first on Investor’s Business Daily.
Biotech stocks Roivant and Pharvaris hit records Tuesday on “blowout” and “bull case” results for lung and swelling disease treatments. The post Why These Two Hot Biotech Stocks Just Surged To Record Highs appeared first on Investor’s Business Daily.
Novartis and Ionis’ high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. The post How Novartis And Ionis’ High-Profile Failure Reverberated Through Biopharma appeared first on Investor’s Business Daily.
Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling. The post Novartis, Ionis Tumble On Surprise Flop For Heart Drug appeared first on Investor’s Business Daily.
Exelixis is Friday’s IBD Stock Of The Day. Shares have recovered from a post second-quarter drop and are now trading in a buy zone. The post IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out…
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck’s blockbuster, Keytruda. The post Summit Packs A Punch For Merck’s Keytruda — But Not Everyone Is Sold appeared first on Investor’s Business Daily.
Climb Bio reversed course Thursday despite potential “best-in-class” data for its experimental kidney disease treatment. The post Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded appeared first on Investor’s Business Daily.
